Biomarkers for radiographic progression in rheumatoid arthritis

Current Pharmaceutical Design

Volumn 21, Issue 2, 2015, Pages 147-169

  Krabben, A ^a   Huizinga, T W J ^a   van der Helm van Mil, A H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biological marker; Biomarkers; Genetics; Magnetic resonance imaging; Radiography; Rheumatoid arthritis; Ultrasound

Indexed keywords

AGGRECANASE 2; AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CD40 ANTIGEN; CXCL13 CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DICKKOPF 1 PROTEIN; GELATINASE B; GRANZYME B; HLA DRB1 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; METHOTREXATE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; PROTEIN KREMEN1; PROTEINASE; SCLEROSTIN; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ARTICLE; BONE EROSION; BONE MARROW EDEMA; BONE RADIOGRAPHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ECHOGRAPHY; EXTRACELLULAR MATRIX; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; INFLAMMATION; JOINT DESTRUCTION; LONGITUDINAL STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYNOVITIS; TENOSYNOVITIS; GENETICS; METABOLISM; PATHOLOGY; RADIOGRAPHY;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; HUMANS;

EID: 84924291618     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140825122525     Document Type: Article

References (118)

1. van der Helm-van Mil AH, Knevel R, van der Heijde D, Huizinga TW. How to avoid phenotypic misclassification in using joint destruction as an outcome measure for rheumatoid arthritis? Rheumatology (Oxford) 2010; 49(8): 1429-35.
2. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44(9): 2009-17.
3. Landewe R, van der Heijde D, Klareskog L, van VR, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006; 54(10): 3119-25.
4. Combe B, Cantagrel A, Goupille P, et al. Predictive factors of 5- year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol 2003; 30(11): 2344-9.
5. Combe B. Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23(1): 59-69.
6. Bathon J, Robles M, Ximenes AC, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 2011; 70(11): 1949-56.
7. Sanmarti R, Gomez A, Ercilla G, et al. Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting. Rheumatology (Oxford) 2003; 42(9): 1044-9.
8. Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford) 2002; 41(2): 196-204.
9. Nell-Duxneuner V, Machold K, Stamm T, et al. Autoantibody profiling in patients with very early rheumatoid arthritis: a followup study. Ann Rheum Dis 2010; 69(1): 169-74.
10. Sharp JT, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62(4): 537-44.
11. Knevel R, Lukas C, van der Heijde D, Rincheval N, Combe B, van der Helm-van Mil AH Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phase. Ann Rheum Dis 2013; 72(4): 590-5.
12. van der Heijde DM. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996; 10(3): 435-53.
13. Larsen A. The value of individual joints for radiologic assessment of rheumatoid arthritis. Scand J Rheumatol 1976; 5(2): 119-23.
14. Knevel R, Tsonaka R, le CS, et al. Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol 2013; 42(3): 182-9.
15. Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003; 62(7): 611-6.
16. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3): 89-95.
17. Syversen SW, Landewe R, van der Heijde D, et al. Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. J Rheumatol 2009; 36(8): 1769-84.
18. Knevel R, Grondal G, Huizinga TW, et al. Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2012; 71(5): 707-9.
19. Too CL, Yahya A, Murad S, et al. Smoking interacts with HLADRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther 2012; 14(2): R89.
20. Gregersen PK. Susceptibility genes for rheumatoid arthritis - a rapidly expanding harvest. Bull NYU Hosp Jt Dis 2010; 68(3): 179-82.
21. van der Helm-van Mil AH, Huizinga TW, Schreuder GM, Breedveld FC, de Vries RR, Toes RE. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis Rheum 2005; 52(9): 2637-44.
22. Lie BA, Viken MK, Odegard S, et al. Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10- year longitudinal study. Ann Rheum Dis 2007; 66(12): 1604-9.
23. Marinou I, Healy J, Mewar D, et al. Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum 2007; 56(8): 2549-56.
24. Karlson EW, Chibnik LB, Cui J, et al. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 2008; 67(3): 358-63.
25. Pierer M, Kaltenhauser S, Arnold S, et al. Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients. Arthritis Res Ther 2006; 8(3): R75.
26. Steer S, Lad B, Grumley JA, Kingsley GH, Fisher SA. Association of R602W in a protein tyrosine phosphatase gene with a high risk of rheumatoid arthritis in a British population: evidence for an early onset/disease severity effect. Arthritis Rheum 2005; 52(1): 358-60.
27. van Nies JA, Knevel R, Daha N, et al. The PTPN22 susceptibility risk variant is not associated with the rate of joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis. Ann Rheum Dis 2010; 69(9): 1730-1.
28. Maxwell JR, Marinou I, Kuet KP, et al. Rheumatoid arthritisassociated polymorphisms at 6q23 are associated with radiological damage in autoantibody-positive RA. J Rheumatol 2012; 39(9): 1781-5.
29. Scherer HU, van der Linden MP, Kurreeman FA, et al. Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2010; 69(3): 567-70.
30. Knevel R, de Rooy DP, Gregersen PK, et al. Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts. Ann Rheum Dis 2012; 71(10): 1753-5.
31. Viatte S, Plant D, Lunt M, et al. Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study further replicates the TRAF1 association with radiological damage. J Rheumatol 2013; 40(2): 144-56.
32. Kurreeman FA, Padyukov L, Marques RB, et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med 2007; 4(9): e278.
33. van der Linden MP, Feitsma AL, le CS, et al. Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis Rheum 2009; 60(8): 2242-7.
34. Knevel R, de Rooy DP, Zhernakova A, et al. Association of variants in IL2RA with progression of joint destruction in Rheumatoid Arthritis. Arthritis Rheum 2013 Mar 25.
35. Kleyer A, Finzel S, Rech J, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2013 Mar 21.
36. Genevay S, Di Giovine FS, Perneger TV, et al. Association of interleukin-4 and interleukin-1B gene variants with Larsen score progression in rheumatoid arthritis. Arthritis Rheum 2002; 47(3): 303-9.
37. Johnsen AK, Plenge RM, Butty V, et al. A broad analysis of IL1 polymorphism and rheumatoid arthritis. Arthritis Rheum 2008; 58(7): 1947-57.
38. Buchs N, Di Giovine FS, Silvestri T, Vannier E, Duff GW, Miossec P. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun 2001; 2(4): 222-8.
39. Marotte H, Farge P, Gaudin P, Alexandre C, Mougin B, Miossec P. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 2006; 65(7): 905-9.
40. Prots I, Skapenko A, Wendler J, et al. Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis. Arthritis Rheum 2006; 54(5): 1491-500.
41. Krabben A, Wilson AG, de Rooy DP, et al. Brief Report: Association of Genetic Variants in the IL4 and IL4R Genes With the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts. Arthritis Rheum 2013; 65(12): 3051-7.
42. Marinou I, Till SH, Moore DJ, Wilson AG. Lack of association or interactions between the IL-4, IL-4Ralpha and IL-13 genes, and rheumatoid arthritis. Arthritis Res Ther 2008; 10(4): R80.
43. Huizinga TW, Keijsers V, Yanni G, et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology (Oxford) 2000; 39(11): 1180-8.
44. Cantagrel A, Navaux F, Loubet-Lescoulie P, et al. Interleukin- 1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42(6): 1093-100.
45. Pawlik A, Kurzawski M, Szklarz BG, Herczynska M, Drozdzik M. Interleukin-10 promoter polymorphism in patients with rheumatoid arthritis. Clin Rheumatol 2005; 24(5): 480-4.
46. Knevel R, Krabben A, Brouwer E, et al. Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis 2012; 71(10): 1651-7.
47. Han SW, Sa KH, Kim SI, et al. FCRL3 gene polymorphisms contribute to the radiographic severity rather than susceptibility of rheumatoid arthritis. Hum Immunol 2012; 73(5): 537-42.
48. Maehlen MT, Nordang GB, Syversen SW, et al. FCRL3 -169C/C genotype is associated with anti-citrullinated protein antibodypositive rheumatoid arthritis and with radiographic progression. J Rheumatol 2011; 38(11): 2329-35.
49. Sugiura Y, Niimi T, Sato S, et al. Transforming growth factor beta1 gene polymorphism in rheumatoid arthritis. Ann Rheum Dis 2002; 61(9): 826-8.
50. Kim SY, Han SW, Kim GW, Lee JM, Kang YM. TGF-beta1 polymorphism determines the progression of joint damage in rheumatoid arthritis. Scand J Rheumatol 2004; 33(6): 389-94.
51. Mattey DL, Nixon N, Dawes PT, Kerr J. Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis. Ann Rheum Dis 2005; 64(8): 1190-4.
52. de Rooy DP, Yeremenko NG, Wilson AG, et al. Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2013; 72(5): 769-75.
53. Knevel R, Krabben A, Wilson AG, et al. A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 2013; 65(3): 582-9.
54. Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005; 434(7033): 648-52.
55. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993; 36(9): 1214-22.
56. Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434(7033): 644-8.
57. Constantin A, Lauwers-Cances V, Navaux F, et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: Association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 2002; 46(7): 1754-62.
58. Mattey DL, Nixon NB, Dawes PT, Ollier WE, Hajeer AH. Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun 2004; 5(2): 147-9.
59. Dorr S, Lechtenbohmer N, Rau R, et al. Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis. Arthritis Res Ther 2004; 6(3): R199-R207.
60. de Rooy DP, Zhernakova A, Tsonaka R, et al. A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 2013 May 21.
61. Knevel R, Klein K, Somers K, et al. Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Ann Rheum Dis 2013 Aug 16.
62. Bukhari M, Thomson W, Naseem H, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007; 56(9): 2929-35.
63. Courvoisier N, Dougados M, Cantagrel A, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 2008; 10(5): R106.
64. Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TP, et al. Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002; 47(4): 383-90.
65. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti- CCP). Ann Rheum Dis 2004; 63(9): 1090-5.
66. Kaltenhauser S, Wagner U, Schuster E, et al. Immunogenetic markers and seropositivity predict radiological progression in early rheumatoid arthritis independent of disease activity. J Rheumatol 2001; 28(4): 735-44.
67. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64(2): 196-201.
68. Mewar D, Coote A, Moore DJ, et al. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 2006; 8(4): R128.
69. Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008; 67(2): 212-7.
70. Vencovsky J, Machacek S, Sedova L, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62(5): 427-30.
71. van der Linden MP, van der Woude D, Ioan-Facsinay A, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60(8): 2232-41.
72. Harris ML, Darrah E, Lam GK, et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 2008; 58(7): 1958-67.
73. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011; 108(42): 17372-7.
74. Knevel R, van Nies JA, le CS, Huizinga TW, Brouwer E, van der Helm-van Mil AH. Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis. Ann Rheum Dis 2013; 72(2): 307-8.
75. Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003; 62(11): 1094-9.
76. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosylpyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002; 46(1): 21-30.
77. Jansen LM, van dH-B I, Lems WF, et al. Serological bone markers and joint damage in early polyarthritis. J Rheumatol 2004; 31(8): 1491-6.
78. Le L X, Brazier M, Mejjad O, et al. Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort. Arthritis Care Res (Hoboken) 2010; 62(12): 1739-47.
79. Young-Min S, Cawston T, Marshall N, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007; 56(10): 3236-47.
80. den Broeder AA, Joosten LA, Saxne T, et al. Long term antitumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002; 61(4): 311-8.
81. Roux-Lombard P, Eberhardt K, Saxne T, Dayer JM, Wollheim FA. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5- year study. Rheumatology (Oxford) 2001; 40(5): 544-51.
82. Garnero P, Landewe R, Boers M, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002; 46(11): 2847-56.
83. Jensen T, Klarlund M, Hansen M, Jensen KE, Skjodt H, Hyldstrup L. Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density, and radiographic outcome. J Rheumatol 2004; 31(9): 1698-708.
84. Krabben A, Knevel R, Huizinga TWJ, Cavet G, van der Helm-van Mil AH. Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritis. The Journal of Rheumatology. In press 2013.
85. Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A. Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. Ann Rheum Dis 2004; 63(2): 216-7.
86. Geusens PP, Landewe RB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54(6): 1772-7.
87. van Tuyl LH, Voskuyl AE, Boers M, et al. Baseline RANKL: OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 2010; 69(9): 1623-8.
88. Meeuwisse CM, van der Linden MP, Rullmann TA, et al. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum 2011; 63(5): 1265-73.
89. McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998; 57(6): 350-6.
90. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009; 68(3): 384-90.
91. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010; 69(10): 1789-95.
92. Boyesen P, Haavardsholm EA, van der Heijde D, et al. Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients. Ann Rheum Dis 2011; 70(1): 176-9.
93. Boyesen P, Haavardsholm EA, Ostergaard M, van der Heijde D, Sesseng S, Kvien TK. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 2011; 70(3): 428-33.
94. Haavardsholm EA, Boyesen P, Ostergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008; 67(6): 794-800.
95. McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999; 58(3): 156-63.
96. McQueen FM, Benton N, Perry D, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48(7): 1814-27.
97. Lindegaard HM, Vallo J, Horslev-Petersen K, Junker P, Ostergaard M. Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study. Ann Rheum Dis 2006; 65(9): 1208-12.
98. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003; 48(1): 64-71.
99. Hoving JL, Buchbinder R, Hall S, et al. A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. J Rheumatol 2004; 31(4): 663-75.
100. Kamishima T, Tanimura K, Shimizu M, et al. Monitoring antiinterleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger. Skeletal Radiol 2011; 40(6): 745-55.
101. Ostergaard M, Hansen M, Stoltenberg M, et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum 2003; 48(8): 2128-31.
102. Scheel AK, Hermann KG, Ohrndorf S, et al. Prospective 7 year follow up imaging study comparing radiography, ultrasonography, and magnetic resonance imaging in rheumatoid arthritis finger joints. Ann Rheum Dis 2006; 65(5): 595-600.
103. Mundwiler ML, Maranian P, Brown DH, et al. The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study. Arthritis Res Ther 2009; 11(3): R94.
104. Dougados M, Devauchelle-Pensec V, Ferlet JF, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 2013; 72(5): 665-71.
105. Lillegraven S, Boyesen P, Hammer HB, et al. Tenosynovitis of the extensor carpi ulnaris tendon predicts erosive progression in early rheumatoid arthritis. Ann Rheum Dis 2011; 70(11): 2049-50.
106. Szkudlarek M, Narvestad E, Klarlund M, Court-Payen Thomsen HS, Ostergaard M. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination. Arthritis Rheum 2004; 50(7): 2103-12.
107. Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le L, X. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther 2012; 14(6): R249.
108. Lillegraven S, Paynter N, Prince FH, et al. Performance of matrixbased risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65(4): 526-33.
109. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48(9): 1114-21.
110. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010; 69(7): 1333-7.
111. Dadoun S, Zeboulon-Ktorza N, Combescure C, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013; 80(1): 29-33.
112. van Nies JA, de JZ, van der Helm-van Mil AH, Knevel R, le CS, Huizinga TW. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology (Oxford) 2010; 49(11): 2210-6.
113. van der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009; 60(8): 2262-71.
114. Goronzy JJ, Matteson EL, Fulbright JW, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004; 50(1): 43-54.
115. Knevel R, de Rooy DP, Gregersen PK, et al. Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts. Ann Rheum Dis 2012; 71(10): 1753-5.
116. Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003; 42(1): 83-8.
117. Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000; 43(4): 852-8.
118. Posthumus MD, Limburg PC, Westra J, et al. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology (Oxford) 1999; 38(11): 1081-7.